Back to News
Market Impact: 0.15
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis
Source: Newswire
Healthcare & BiotechArtificial IntelligenceTechnology & Innovation
Companies will use AI-enabled digital pathology and spatial single-fiber analysis to characterize the mechanistic effects of MTX-474 in systemic sclerosis. The initiative may improve understanding of the drug candidate's biological activity, but no clinical efficacy, financial, or regulatory results were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- South Korea’s exports hit record high on AI boom
- Asian stocks dip, bonds in focus after torrid September
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Asia stocks rise on chipmaker gains, soft U.S. inflation; Nikkei outperforms
- We're raising our Micron price target after an incredible quarter and robust guidance
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow